United States: These 64 Drugs Face Patent Expirations and Generic Entry in 2026 - 2027

Generic name: morphine sulfate; naltrexone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 19, 2027
Generic Entry Controlled by: United States Patent 8,158,156

EMBEDA is a drug marketed by Alpharma Pharms. There are seven patents protecting this drug and four Paragraph IV challenges.

This drug has seventy-four patent family members in twenty-three countries.

See drug price trends for EMBEDA.

The generic ingredient in EMBEDA is morphine sulfate; naltrexone hydrochloride. There are twenty-three drug master file entries for this API. Additional details are available on the morphine sulfate; naltrexone hydrochloride profile page.

Generic name: betrixaban
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 08, 2026
Generic Entry Controlled by: United States Patent 7,598,276

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

Generic name: omega-3-carboxylic acids
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 20, 2026
Generic Entry Controlled by: United States Patent 7,960,370

EPANOVA is a drug marketed by Astrazeneca. There are four patents protecting this drug.

This drug has eighty-five patent family members in forty-one countries.

The generic ingredient in EPANOVA is omega-3-carboxylic acids. There is one drug master file entry for this API. Additional details are available on the omega-3-carboxylic acids profile page.

Generic name: simeprevir sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 28, 2026
Generic Entry Controlled by: United States Patent 8,349,869

OLYSIO is a drug marketed by Janssen Prods. There are eight patents protecting this drug.

This drug has sixty-four patent family members in forty-one countries.

See drug price trends for OLYSIO.

The generic ingredient in OLYSIO is simeprevir sodium. There is one drug master file entry for this API. Additional details are available on the simeprevir sodium profile page.

Generic name: boceprevir
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 17, 2027
Generic Entry Controlled by: United States Patent 8,119,602

VICTRELIS is a drug marketed by Merck Sharp Dohme. There are two patents protecting this drug.

This drug has twenty-seven patent family members in seventeen countries.

The generic ingredient in VICTRELIS is boceprevir. Additional details are available on the boceprevir profile page.

Generic name: tafamidis
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 19, 2026
Generic Entry Controlled by: United States Patent 7,214,695

VYNDAMAX is a drug marketed by Foldrx Pharms. There are three patents protecting this drug.

This drug has sixty-six patent family members in twenty-seven countries. There has been litigation on patents covering VYNDAMAX

See drug price trends for VYNDAMAX.

The generic ingredient in VYNDAMAX is tafamidis. One supplier is listed for this generic product. Additional details are available on the tafamidis profile page.

Generic name: tafamidis meglumine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 19, 2026
Generic Entry Controlled by: United States Patent 7,214,695

VYNDAQEL is a drug marketed by Foldrx Pharms. There are two patents protecting this drug.

This drug has thirty-five patent family members in seventeen countries. There has been litigation on patents covering VYNDAQEL

See drug price trends for VYNDAQEL.

The generic ingredient in VYNDAQEL is tafamidis meglumine. One supplier is listed for this generic product. Additional details are available on the tafamidis meglumine profile page.

Generic name: vorinostat
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 16, 2026
Generic Entry Controlled by: United States Patent 8,093,295

ZOLINZA is a drug marketed by Msd Sub Merck. There are three patents protecting this drug.

This drug has one hundred and thirty-one patent family members in thirty-five countries.

See drug price trends for ZOLINZA.

The generic ingredient in ZOLINZA is vorinostat. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the vorinostat profile page.

Generic name: fish oil triglycerides
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 30, 2026
Generic Entry Controlled by: United States Patent 9,566,260

OMEGAVEN is a drug marketed by Fresenius Kabi Usa. There is one patent protecting this drug.

This drug has five patent family members in four countries. There has been litigation on patents covering OMEGAVEN

See drug price trends for OMEGAVEN.

The generic ingredient in OMEGAVEN is fish oil triglycerides. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the fish oil triglycerides profile page.

Generic name: rolapitant hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 04, 2027
Generic Entry Controlled by: United States Patent 8,178,550

VARUBI is a drug marketed by Tersera. There are eight patents protecting this drug.

This drug has one hundred and fifty-eight patent family members in thirty-five countries.

The generic ingredient in VARUBI is rolapitant hydrochloride. One supplier is listed for this generic product. Additional details are available on the rolapitant hydrochloride profile page.

Generic name: afamelanotide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 08, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SCENESSE is a drug marketed by Clivunel Inc. There is one patent protecting this drug.

This drug has twenty-three patent family members in sixteen countries.

See drug price trends for SCENESSE.

The generic ingredient in SCENESSE is afamelanotide. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the afamelanotide profile page.

Generic name: ferric carboxymaltose
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 05, 2027
Generic Entry Controlled by: United States Patent 7,612,109

INJECTAFER is a drug marketed by Am Regent. There are six patents protecting this drug.

This drug has seventy-one patent family members in thirty-two countries. There has been litigation on patents covering INJECTAFER

See drug price trends for INJECTAFER.

The generic ingredient in INJECTAFER is ferric carboxymaltose. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ferric carboxymaltose profile page.

Generic name: triheptanoin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 30, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DOJOLVI is a drug marketed by Ultragenyx Pharm Inc. There are two patents protecting this drug.

This drug has thirty-six patent family members in seventeen countries.

See drug price trends for DOJOLVI.

The generic ingredient in DOJOLVI is triheptanoin. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the triheptanoin profile page.

Generic name: abametapir
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 28, 2026
Generic Entry Controlled by: United States Patent 7,812,163

XEGLYZE is a drug marketed by Hatchtech. There are two patents protecting this drug.

This drug has thirty-six patent family members in fifteen countries.

The generic ingredient in XEGLYZE is abametapir. Additional details are available on the abametapir profile page.

Generic name: retapamulin
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 14, 2027
Generic Entry Controlled by: United States Patent 7,875,630

ALTABAX is a drug marketed by Almirall. There is one patent protecting this drug.

This drug has thirteen patent family members in six countries.

See drug price trends for ALTABAX.

The generic ingredient in ALTABAX is retapamulin. Additional details are available on the retapamulin profile page.

Generic name: sinecatechins
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 02, 2026
Generic Entry Controlled by: United States Patent 5,795,911

VEREGEN is a drug marketed by Ani Pharms. There is one patent protecting this drug.

This drug has thirty-one patent family members in twenty countries. There has been litigation on patents covering VEREGEN

See drug price trends for VEREGEN.

The generic ingredient in VEREGEN is sinecatechins. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the sinecatechins profile page.

Generic name: loxapine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 23, 2026
Generic Entry Controlled by: United States Patent 8,387,612

ADASUVE is a drug marketed by Nova Pneuma. There is one patent protecting this drug.

This drug has twenty-one patent family members in six countries. There has been litigation on patents covering ADASUVE

See drug price trends for ADASUVE.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this API. Additional details are available on the loxapine profile page.

Generic name: remimazolam besylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 10, 2027
Generic Entry Controlled by: United States Patent 10,961,250

BYFAVO is a drug marketed by Acacia. There are eleven patents protecting this drug.

This drug has fifty-three patent family members in twenty-four countries. There has been litigation on patents covering BYFAVO

See drug price trends for BYFAVO.

The generic ingredient in BYFAVO is remimazolam besylate. One supplier is listed for this generic product. Additional details are available on the remimazolam besylate profile page.

Generic name: telavancin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 01, 2027
Generic Entry Controlled by: United States Patent 7,531,623

VIBATIV is a drug marketed by Cumberland. There is one patent protecting this drug.

This drug has thirty-three patent family members in eighteen countries.

See drug price trends for VIBATIV.

The generic ingredient in VIBATIV is telavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the telavancin hydrochloride profile page.

Generic name: patiromer sorbitex calcium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 29, 2027
Generic Entry Controlled by: United States Patent 8,282,913

VELTASSA is a drug marketed by Vifor Pharma. There are seven patents protecting this drug.

This drug has two hundred and seven patent family members in twenty-seven countries. There has been litigation on patents covering VELTASSA

See drug price trends for VELTASSA.

The generic ingredient in VELTASSA is patiromer sorbitex calcium. One supplier is listed for this generic product. Additional details are available on the patiromer sorbitex calcium profile page.

Generic name: teduglutide recombinant
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 16, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GATTEX KIT is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has eight patent family members in seven countries. There has been litigation on patents covering GATTEX KIT

The generic ingredient in GATTEX KIT is teduglutide recombinant. There is one drug master file entry for this API. Additional details are available on the teduglutide recombinant profile page.

Generic name: omacetaxine mepesuccinate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: October 26, 2026
Generic Entry Controlled by: United States Patent 6,987,103

SYNRIBO is a drug marketed by Teva Pharms Intl. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has twenty-one patent family members in twelve countries.

See drug price trends for SYNRIBO.

The generic ingredient in SYNRIBO is omacetaxine mepesuccinate. There are two drug master file entries for this API. Additional details are available on the omacetaxine mepesuccinate profile page.

Generic name: nusinersen sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 11, 2027
Generic Entry Controlled by: United States Patent 7,838,657

SPINRAZA is a drug marketed by Biogen Idec. There are seven patents protecting this drug.

This drug has one hundred and six patent family members in twenty-eight countries. There has been litigation on patents covering SPINRAZA

See drug price trends for SPINRAZA.

The generic ingredient in SPINRAZA is nusinersen sodium. One supplier is listed for this generic product. Additional details are available on the nusinersen sodium profile page.

Generic name: florbetapir f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 30, 2027
Generic Entry Controlled by: United States Patent 7,687,052

AMYVID is a drug marketed by Avid Radiopharms Inc. There are two patents protecting this drug.

This drug has fifty-one patent family members in thirty-three countries. There has been litigation on patents covering AMYVID

The generic ingredient in AMYVID is florbetapir f-18. One supplier is listed for this generic product. Additional details are available on the florbetapir f-18 profile page.

Generic name: fluciclovine f-18
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 28, 2026
Generic Entry Controlled by: United States Patent 10,010,632

AXUMIN is a drug marketed by Blue Earth. There are eight patents protecting this drug.

This drug has thirty patent family members in sixteen countries. There has been litigation on patents covering AXUMIN

The generic ingredient in AXUMIN is fluciclovine f-18. One supplier is listed for this generic product. Additional details are available on the fluciclovine f-18 profile page.

Generic name: gallium dotatoc ga-68
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: August 21, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GALLIUM DOTATOC GA 68 is a drug marketed by

The generic ingredient in GALLIUM DOTATOC GA 68 is gallium dotatoc ga-68. There are sixteen drug master file entries for this API. Additional details are available on the gallium dotatoc ga-68 profile page.

Generic name: peramivir
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 12, 2027
Generic Entry Controlled by: United States Patent 10,391,075

RAPIVAB is a drug marketed by Biocryst. There are two patents protecting this drug.

This drug has forty-three patent family members in fourteen countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

Generic name: golodirsen
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 12, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYONDYS 53 is a drug marketed by Sarepta Theraps Inc. There is one patent protecting this drug.

This drug has thirty patent family members in thirteen countries. There has been litigation on patents covering VYONDYS 53

The generic ingredient in VYONDYS 53 is golodirsen. One supplier is listed for this generic product. Additional details are available on the golodirsen profile page.

Generic name: brilliant blue g
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 20, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TISSUEBLUE is a drug marketed by Dutch Ophthalmic.

The generic ingredient in TISSUEBLUE is brilliant blue g. One supplier is listed for this generic product. Additional details are available on the brilliant blue g profile page.

Generic name: mipomersen sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 29, 2027
Generic Entry Controlled by: United States Patent 7,511,131

KYNAMRO is a drug marketed by Kastle Theraps Llc. There is one patent protecting this drug.

This drug has forty-five patent family members in eleven countries. There has been litigation on patents covering KYNAMRO

See drug price trends for KYNAMRO.

The generic ingredient in KYNAMRO is mipomersen sodium. Additional details are available on the mipomersen sodium profile page.

Generic name: pasireotide diaspartate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 14, 2026
Generic Entry Controlled by: United States Patent 7,473,761

SIGNIFOR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

This drug has forty-five patent family members in thirty-three countries.

See drug price trends for SIGNIFOR.

The generic ingredient in SIGNIFOR is pasireotide diaspartate. One supplier is listed for this generic product. Additional details are available on the pasireotide diaspartate profile page.

Generic name: olodaterol hydrochloride; tiotropium bromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 19, 2027
Generic Entry Controlled by: United States Patent 7,727,984

STIOLTO RESPIMAT is a drug marketed by Boehringer Ingelheim. There are five patents protecting this drug.

This drug has one hundred and twenty-three patent family members in forty countries. There has been litigation on patents covering STIOLTO RESPIMAT

See drug price trends for STIOLTO RESPIMAT.

The generic ingredient in STIOLTO RESPIMAT is olodaterol hydrochloride; tiotropium bromide. One supplier is listed for this generic product. Additional details are available on the olodaterol hydrochloride; tiotropium bromide profile page.

Generic name: olodaterol hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 19, 2027
Generic Entry Controlled by: United States Patent 7,727,984

STRIVERDI RESPIMAT is a drug marketed by Boehringer Ingelheim. There is one patent protecting this drug.

This drug has fifty-one patent family members in thirty-six countries. There has been litigation on patents covering STRIVERDI RESPIMAT

See drug price trends for STRIVERDI RESPIMAT.

The generic ingredient in STRIVERDI RESPIMAT is olodaterol hydrochloride. One supplier is listed for this generic product. Additional details are available on the olodaterol hydrochloride profile page.

Generic name: bupropion hydrobromide
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 27, 2026
Generic Entry Controlled by: United States Patent 7,572,935

APLENZIN is a drug marketed by Bausch. There are eight patents protecting this drug and three Paragraph IV challenges. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in eighteen countries. There has been litigation on patents covering APLENZIN

See drug price trends for APLENZIN.

The generic ingredient in APLENZIN is bupropion hydrobromide. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrobromide profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 04, 2027
Generic Entry Controlled by: United States Patent 9,107,837

CONTRAVE is a drug marketed by Nalpropion. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty-seven patent family members in forty-five countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: gabapentin enacarbil
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 10, 2026
Generic Entry Controlled by: United States Patent 8,026,279

HORIZANT is a drug marketed by Azurity. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has seventy-three patent family members in twenty-four countries.

See drug price trends for HORIZANT.

The generic ingredient in HORIZANT is gabapentin enacarbil. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the gabapentin enacarbil profile page.

Generic name: bazedoxifene acetate; estrogens, conjugated
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 10, 2027
Generic Entry Controlled by: United States Patent 7,683,051

DUAVEE is a drug marketed by Wyeth Pharms. There is one patent protecting this drug.

This drug has twenty-two patent family members in twenty countries.

See drug price trends for DUAVEE.

The generic ingredient in DUAVEE is bazedoxifene acetate; estrogens, conjugated. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the bazedoxifene acetate; estrogens, conjugated profile page.

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 26, 2027
Generic Entry Controlled by: United States Patent 8,981,103

GENVOYA is a drug marketed by Gilead Sciences Inc. There are nine patents protecting this drug.

This drug has four hundred and sixty-three patent family members in fifty-three countries. There has been litigation on patents covering GENVOYA

See drug price trends for GENVOYA.

The generic ingredient in GENVOYA is cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate profile page.

Generic name: alogliptin benzoate; metformin hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 27, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KAZANO is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has ninety patent family members in forty-one countries. There has been litigation on patents covering KAZANO

See drug price trends for KAZANO.

The generic ingredient in KAZANO is alogliptin benzoate; metformin hydrochloride. There are ten drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate; metformin hydrochloride profile page.

Generic name: dienogest; estradiol valerate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: May 13, 2026
Generic Entry Controlled by: United States Patent 8,071,577

NATAZIA is a drug marketed by Bayer Hlthcare. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has ninety patent family members in thirty-nine countries. There has been litigation on patents covering NATAZIA

See drug price trends for NATAZIA.

The generic ingredient in NATAZIA is dienogest; estradiol valerate. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the dienogest; estradiol valerate profile page.

Generic name: alogliptin benzoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 27, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NESINA is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has sixty-nine patent family members in thirty-seven countries. There has been litigation on patents covering NESINA

See drug price trends for NESINA.

The generic ingredient in NESINA is alogliptin benzoate. There are ten drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the alogliptin benzoate profile page.

Generic name: alpelisib
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 18, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PIQRAY is a drug marketed by Novartis. There are two patents protecting this drug.

This drug has sixty patent family members in fifty countries.

See drug price trends for PIQRAY.

The generic ingredient in PIQRAY is alpelisib. One supplier is listed for this generic product. Additional details are available on the alpelisib profile page.

Generic name: cobicistat; darunavir
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 26, 2027
Generic Entry Controlled by: United States Patent 7,700,645

PREZCOBIX is a drug marketed by Janssen Prods. There are three patents protecting this drug.

This drug has three hundred and fifty-four patent family members in forty-one countries. There has been litigation on patents covering PREZCOBIX

See drug price trends for PREZCOBIX.

The generic ingredient in PREZCOBIX is cobicistat; darunavir. There are five drug master file entries for this API. Additional details are available on the cobicistat; darunavir profile page.

Generic name: edoxaban tosylate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 18, 2027
Generic Entry Controlled by: United States Patent 7,365,205

SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.

Generic name: bedaquiline fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 21, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SIRTURO is a drug marketed by Janssen Therap. There are two patents protecting this drug.

This drug has ninety-seven patent family members in thirty-nine countries.

See drug price trends for SIRTURO.

The generic ingredient in SIRTURO is bedaquiline fumarate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the bedaquiline fumarate profile page.

Generic name: cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 26, 2027
Generic Entry Controlled by: United States Patent 8,981,103

STRIBILD is a drug marketed by Gilead Sciences Inc. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has four hundred and five patent family members in forty-eight countries. There has been litigation on patents covering STRIBILD

See drug price trends for STRIBILD.

The generic ingredient in STRIBILD is cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate profile page.

Generic name: cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 26, 2026
Generic Entry Controlled by: United States Patent 7,700,645

SYMTUZA is a drug marketed by Janssen Prods. There are six patents protecting this drug.

This drug has four hundred and twenty-three patent family members in forty-six countries. There has been litigation on patents covering SYMTUZA

See drug price trends for SYMTUZA.

The generic ingredient in SYMTUZA is cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the cobicistat; darunavir; emtricitabine; tenofovir alafenamide fumarate profile page.

Generic name: aliskiren hemifumarate; valsartan
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 03, 2026
Generic Entry Controlled by: United States Patent 8,168,616

VALTURNA is a drug marketed by Novartis. There is one patent protecting this drug.

This drug has ninety-three patent family members in thirty-one countries.

The generic ingredient in VALTURNA is aliskiren hemifumarate; valsartan. There are four drug master file entries for this API. Additional details are available on the aliskiren hemifumarate; valsartan profile page.

Generic name: elvitegravir
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 26, 2027
Generic Entry Controlled by: United States Patent 8,981,103

VITEKTA is a drug marketed by Gilead Sciences Inc. There are three patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has ninety-two patent family members in thirty-six countries. There has been litigation on patents covering VITEKTA

The generic ingredient in VITEKTA is elvitegravir. There are six drug master file entries for this API. Additional details are available on the elvitegravir profile page.

Generic name: histrelin acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 16, 2026
Generic Entry Controlled by: United States Patent 8,062,652

SUPPRELIN LA is a drug marketed by Endo Operations. There is one patent protecting this drug.

This drug has three patent family members in three countries.

See drug price trends for SUPPRELIN LA.

The generic ingredient in SUPPRELIN LA is histrelin acetate. There are two drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the histrelin acetate profile page.

Generic name: testosterone undecanoate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 14, 2027
Generic Entry Controlled by: United States Patent 7,718,640

AVEED is a drug marketed by Endo Operations. There are two patents protecting this drug and one Paragraph IV challenge. One tentatively approved generic is ready to enter the market.

This drug has fifty-two patent family members in thirty-eight countries. There has been litigation on patents covering AVEED

See drug price trends for AVEED.

The generic ingredient in AVEED is testosterone undecanoate. There are sixty-nine drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the testosterone undecanoate profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 02, 2026
Generic Entry Controlled by: United States Patent 7,550,433

OMONTYS is a drug marketed by Takeda Pharms Usa. There are two patents protecting this drug.

This drug has twenty-seven patent family members in eighteen countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: chlorhexidine gluconate; isopropyl alcohol
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 25, 2027
Generic Entry Controlled by: United States Patent 7,422,388

CHLORAPREP ONE-STEP is a drug marketed by Becton Dickinson Co.

The generic ingredient in CHLORAPREP ONE-STEP is chlorhexidine gluconate; isopropyl alcohol. There are fifty-eight drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the chlorhexidine gluconate; isopropyl alcohol profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: January 31, 2027
Generic Entry Controlled by: United States Patent 7,834,059

NEVANAC is a drug marketed by Harrow Eye. There is one patent protecting this drug.

This drug has twenty-seven patent family members in twenty-three countries.

See drug price trends for NEVANAC.

The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 28, 2027
Generic Entry Controlled by: United States Patent 7,863,287

ADVIL ALLERGY SINUS is a drug marketed by Haleon Us Holdings. There is one patent protecting this drug.

This drug has thirty-four patent family members in eighteen countries.

The generic ingredient in ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

Generic name: amphetamine; amphetamine aspartate/dextroamphetamine sulfate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 15, 2027
Generic Entry Controlled by: United States Patent 8,747,902

DYANAVEL XR 10 is a drug marketed by Tris Pharma Inc. There are five patents protecting this drug.

This drug has twenty-one patent family members in fourteen countries.

The generic ingredient in DYANAVEL XR 10 is amphetamine; amphetamine aspartate/dextroamphetamine sulfate. There are fifty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the amphetamine; amphetamine aspartate/dextroamphetamine sulfate profile page.

Generic name: avacincaptad pegol sodium
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: November 11, 2026
Generic Entry Controlled by: United States Patent 8,236,773

IZERVAY is a drug marketed by Astellas. There are six patents protecting this drug.

This drug has one hundred and thirteen patent family members in thirty countries.

See drug price trends for IZERVAY.

The generic ingredient in IZERVAY is avacincaptad pegol sodium. One supplier is listed for this generic product. Additional details are available on the avacincaptad pegol sodium profile page.

Generic name: norgestrel
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: July 13, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

OPILL is a drug marketed by Laboratoire Hra.

See drug price trends for OPILL.

The generic ingredient in OPILL is norgestrel. There are twenty-five drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the norgestrel profile page.

Generic name: technetium tc-99m labeled carbon
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: September 29, 2026
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TECHNEGAS KIT is a drug marketed by Cyclomedica. There is one patent protecting this drug.

This drug has fourteen patent family members in ten countries.

The generic ingredient in TECHNEGAS KIT is technetium tc-99m labeled carbon. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the technetium tc-99m labeled carbon profile page.

Generic name: olive oil; soybean oil
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: April 24, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

CLINOLIPID 20% is a drug marketed by Baxter Hlthcare Corp.

The generic ingredient in CLINOLIPID 20% is olive oil; soybean oil. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olive oil; soybean oil profile page.

Generic name: acetylcysteine lysine
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: February 13, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LEGUBETI is a drug marketed by Galephar.

The generic ingredient in LEGUBETI is acetylcysteine lysine. There are three drug master file entries for this API. Additional details are available on the acetylcysteine lysine profile page.

Generic name: copper
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: June 28, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

PARAGARD T 380A is a drug marketed by Coopersurgical.

The generic ingredient in PARAGARD T 380A is copper. There are fifteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the copper profile page.

Generic name: benzgalantamine gluconate
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: December 01, 2026
Generic Entry Controlled by: United States Patent 9,763,953

ZUNVEYL is a drug marketed by Alpha Cognition. There are four patents protecting this drug.

This drug has twenty-six patent family members in seventeen countries. There has been litigation on patents covering ZUNVEYL

The generic ingredient in ZUNVEYL is benzgalantamine gluconate. One supplier is listed for this generic product. Additional details are available on the benzgalantamine gluconate profile page.

Generic name: maralixibat chloride
DrugPatentWatch^® Estimated Patent Expiration / Generic Entry Opportunity Date: March 13, 2027
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

LIVMARLI is a drug marketed by Mirum. There are nine patents protecting this drug.

This drug has one hundred and thirty-four patent family members in twenty-four countries. There has been litigation on patents covering LIVMARLI

See drug price trends for LIVMARLI.

The generic ingredient in LIVMARLI is maralixibat chloride. One supplier is listed for this generic product. Additional details are available on the maralixibat chloride profile page.